An update from the AIBN Director: Highlights from BioAsia 2025
Queensland has once again reinforced its position as a global biotechnology leader at BioAsia 2025, one of the headline life sciences and healthcare conferences, held last month in Hyderabad, India.
With Asia’s biotech industry projected to grow beyond USD $300 billion by 2030, the conference provided a platform to expand collaborations across key sectors, including mRNA vaccine development, AI-driven healthcare, and advanced manufacturing.
The Queensland delegation was led by AIBN’s Professor Alan Rowan and included leading Queensland industry and research institutes to showcase the state’s expertise in biotechnology.
The delegation was coordinated by Trade and Investment Queensland and included the Queensland Minister for Finance, Trade, Employment and Training Ros Bates MP and The Governor of Queensland Her Excellency the Honourable Dr Jeannette Young AC PSM.
Professor Rowan said it was clear that Queensland would continue to be a major force in shaping the future of biotechnology in Asia and beyond.
“The life sciences sector is evolving rapidly,” Professor Rowan said.
“Queensland is at the forefront of biotech innovation and our strong relationships with India and the broader Asian market position us to help drive the future of healthcare.
“From pioneering clinical trials to next-generation therapeutics, Queensland is driving innovation and attracting international investment, while also shaping the future of medicine.
“BioAsia also provided an opportunity to continue to demonstrate UQ’s close partnership with India, including through our joint PhD program with the Indian Institute of Technology Delhi.”
Beyond India, Queensland is engaged with Singapore’s biomanufacturing sector, Japan’s innovation hubs, and South Korea’s digital health industry, leveraging world-class research and commercial expertise to drive new healthcare solutions.
The Queensland delegation included leading institutions and industry, including:
- Griffith University Clinical Trial Unit
- University of Southern Queensland
- Vaxxas
- HealthCare Logic
- Resolian
- QIMR Berghofer
- Clinials
- Southern RNA
- TeleMedC
With new partnerships established and Queensland’s expertise on display, the delegation returns home with a strengthened global network to advance the research and industry sectors here in Australia and in Asia.
Read more:
- Trade mission strengthens India-Queensland biotech ties
- Queensland expands healthcare presence at BioAsia 2025
- Queensland shines on global stage as trade mission hits new level
